Recommended

New webinar: Overcoming critical challenges in AI-driven drug discovery
Watch on demand: Rapid cell-based profiling of multi-target anti-obesity drugs Watch here!
Download now: Unlock the power of stem cell therapy and discover the potential for new therapies for primary open-angle glaucoma
Brand new Beyond the Lab report on antibodies… Download NOW!

List view / Grid view

Articles

Roger Bosse, PhD, Sales Development Team Lead, PerkinElmer
Roger Bosse, PhD, Sales Development Team Lead, PerkinElmer

Expert view: Assays to measure the potency of therapeutic antibodies used in combination with other drugs for Immuno‑Oncology treatments

6 September 2018 | By

Growing evidence reveals that using single immunotherapies to treat oncological disorders may lead to cancer-killing T-cell overdrive,initiating life-threatening autoimmune reactions including cytokinestorm; also known as hypercytokinemia or Cytokine Release Syndrome(CRS). Recently, checkpoint blockade using anti-programmed cell death1 (anti-PD-1) inhibitors became a prevalent approach for stimulatinganti-tumour immune system.

mAb
mAb

Aggregate formation for monoclonal antibodies

5 September 2018 | By

Workflows are generated around the analysis of large protein-derived therapeutics. The use of different analytical techniques is necessary to support drug development and testing, and thus increase generation of these new therapies. One of the areas that is most critical to this process is the determination of aggregates.

Steven Jarvis Head of Pharma and Biotech Segment Strategy, Merck KGaA
Steven Jarvis Head of Pharma and Biotech Segment Strategy, Merck KGaA

Expert view: Managing the complexity of finding new targets and drugging the undruggable

5 September 2018 | By

Assessing targets that are unable – or rather, extremely difficult – to reach pharmacologically, has prevented researchers from achieving desired clinical successes, most notably in the realm of cancer research. However, many advances are being made to shedlight on these difficult yet desirable target areas.

Del Trezise, Head of Applications, BioAnalytics, Sartorius AG
Del Trezise, Head of Applications, BioAnalytics, Sartorius AG

Expert view: New developments in real‑time live‑cell analysis

5 September 2018 | By

Live-cell analysis is now a well-established method that is part of the everyday cell biologist’s armoury for understanding cell biology. For over a decade, the functionality, throughput, and ease of use offered by real-time live-cell analysis has provided a platform for accurate and reproducible cell biology analysis in multiple biomedical…

phenotypic
phenotypic

Human iPSC-derived functional cells are revolutionising phenotypic drug discovery and development

4 September 2018 | By , , ,

Effective drug discovery and development relies largely on the availability of predictive pre-clinical model systems; the absence of which has contributed to late-stage drug failures and high expenditures. New industry acceptance of human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay systems for regulatory safety pharmacology is now resulting in broad…

cell culture processing
cell culture processing

Upstream cell culture processes for the production of therapeutic proteins

4 September 2018 | By

Drugs of biological origin form the backbone of the drug discovery pipelines for many major pharmaceutical companies. These biologic therapeutics can be defined as proteins derived from eukaryotic cell culture processes. The ability of eukaryotic cells to undertake complex post-translational modifications makes them ideal vehicles for manufacturing proteins emerging from…

autophagy
autophagy

Applications of high content screening in autophagy

4 September 2018 | By , ,

Autophagy is an important process to maintain cellular homeostasis and function.1 Basal levels of autophagy are essential for most cells to remove unwanted protein aggregates and damaged organelles in order to prevent diseases.2 However, sometimes cells are unable to maintain physiological stability as a consequence of altered autophagy, which leads…

Drug Target Review 3 2018 magazine
Drug Target Review 3 2018 magazine

Drug Target Review – Issue 3 2018

3 September 2018 | By

In this issue: pharmacological targeting of mitochondrial dysfunction in Parkinson’s disease, the evolving role of three dimensional in-vitro cell culture techniques in drug discovery, and NGS: hunting mysterious ‘Dark Matter Genome’ towards rewriting the rules of genetic diseases.

The changing face in drug discovery

1 September 2018 | By

Over the past decade, pharmaceutical industries have contributed enormously to the discovery of new innovative drugs that have saved countless human lives. Discovering new drugs is a complex team sport that requires an intellectual collaboration across many sectors. These advancements provide powerful tools that arm scientists in the quest for…

Adapting drug discovery to Artificial Intelligence

25 July 2018 | By , , , , ,

Drug discovery has always been challenging; today, more so than ever. While there has been success in addressing many diseases, others remain intractable...